Prospera Financial Services Inc held its position in NewLink Genetics Corp. (NASDAQ:NLNK) during the second quarter, Holdings Channel reports. The institutional investor owned 10,200 shares of the company’s stock at the end of the second quarter. Prospera Financial Services Inc’s holdings in NewLink Genetics Corp. were worth $115,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Parametrica Management Ltd purchased a new position in NewLink Genetics Corp. during the first quarter worth $216,000. Eqis Capital Management Inc. boosted its position in NewLink Genetics Corp. by 4.6% in the second quarter. Eqis Capital Management Inc. now owns 48,109 shares of the company’s stock worth $542,000 after buying an additional 2,102 shares during the period. Spark Investment Management LLC purchased a new position in NewLink Genetics Corp. during the first quarter worth $2,156,000. Geode Capital Management LLC boosted its position in NewLink Genetics Corp. by 5.5% in the first quarter. Geode Capital Management LLC now owns 161,279 shares of the company’s stock worth $2,935,000 after buying an additional 8,356 shares during the period. Finally, Teachers Advisors Inc. boosted its position in NewLink Genetics Corp. by 24.8% in the first quarter. Teachers Advisors Inc. now owns 193,336 shares of the company’s stock worth $3,519,000 after buying an additional 38,400 shares during the period. Institutional investors own 50.10% of the company’s stock.
NewLink Genetics Corp. (NASDAQ:NLNK) traded up 6.14% during mid-day trading on Tuesday, hitting $13.32. 528,962 shares of the stock were exchanged. NewLink Genetics Corp. has a 52-week low of $9.23 and a 52-week high of $46.34. The stock’s market cap is $385.87 million. The stock’s 50 day moving average is $10.69 and its 200 day moving average is $12.84.
NewLink Genetics Corp. (NASDAQ:NLNK) last released its quarterly earnings data on Friday, July 29th. The company reported ($1.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.35. NewLink Genetics Corp. had a negative return on equity of 51.33% and a negative net margin of 316.38%. Analysts forecast that NewLink Genetics Corp. will post ($3.06) EPS for the current fiscal year.
Separately, Zacks Investment Research upgraded shares of NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, July 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. NewLink Genetics Corp. presently has a consensus rating of “Hold” and a consensus target price of $23.29.
NewLink Genetics Corp. Company Profile
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.
Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corp. (NASDAQ:NLNK).
Receive News & Ratings for NewLink Genetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.